The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
In the fourth quarter of fiscal year 2018, the Company entered into a definitive agreement to sell its semiconductor cryogenics business to Edwards Vacuum LLC (a member of the Atlas Copco Group), (the “Disposition”).
The discussion in the notes to these Consolidated Financial Statements, unless otherwise noted, relate solely to the Company's continuing operations.
Please refer to Note 3, “Discontinued Operations” for further information.
The accompanying Consolidated Balance Sheet as of September 30, 2018 was derived from the audited annual consolidated financial statements as of the period then ended.
The targeted changes to the lessor accounting are not applicable to the Company because we are not in the industry to be targeted by the guidance.
The Company is currently evaluating the impact of this ASU.
The ASU does not amend the interim disclosure requirements of ASC 715-20.Item 2.
·    Overview.
In April 2018, we acquired BioSpeciMan Corporation, or BioSpeciMan, a Canadian provider of storage services for biological sample materials.
Please refer to Note 5, “Acquisitions” in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10‑Q for further information on these transactions.
Gross margin was 40.6% for the three months ended March 31, 2019 as compared to 39.7% for the corresponding period of the prior fiscal year, an increase of $18.1 million.
Operating expenses were $66.8 million during the three months ended March 31, 2019 as compared to $52.1 million during the corresponding period of the prior fiscal year, an increase of $14.8 million.